Author(s): Bharti S Fegade, Aishwarya S. Mhatre, Vijay K. Munipalli, Hemant P Magar, Pankaj P Thakur, Ashok Kumar, Vaidun Bhaskar

Email(s): bhartigip@gmail.com , aishwaryasmhatre@gmail.com

DOI: 10.52711/0974-360X.2024.00427   

Address: Bharti S Fegade1*, Aishwarya S. Mhatre1, Vijay K. Munipalli2, Hemant P Magar2, Pankaj P Thakur2, Ashok Kumar2, Vaidun Bhaskar1
1Department of Quality Assurance, Gahlot Institute of Pharmacy, Plot No. 59, Sector -14, Koparkhairane, Navi Mumbai – 400709, Maharashtra, India.
2Analytical Research and Development, Central Drug Testing Laboratory, Zonal FDA Bhavan, GMSD Compound, Belasis Road, Mumbai Central, Mumbai – 400008, Maharashtra, India.
*Corresponding Author

Published In:   Volume - 17,      Issue - 6,     Year - 2024


ABSTRACT:
A simple, precise, new stability indicating RP-HPLC method was developed and validated for the determination of deferiprone in its solid pharmaceutical dosage form. The reverse phase high performance liquid chromatography (RP-HPLC) was used for the quantitative determination of deferiprone using UV/VIS detector. The chromatographic separation was carried out on Zorbax SB C18 column (4.6*250 mm,5 um) with a mobile phase of methanol-buffer (25mM Potassium dihydrogen phosphate and 1ml TEA in 1000 ml at (PH 3.5)) in the (40:60% v/v) ratio. The detection wavelength was found to be 280nm with a flow rate 0.6 ml/min and temperature of 40°C.The retention time of deferiprone was found to be 4.7 min. The developed method was validated in accordance with ICH guidelines (ICH Q2 R1). The calibration curve was found to be linear over the concentration range of 10-150µg/ml and shows correlation coefficient (r2) of 0.999. Deferiprone was found to have LOD and LOQ values of 3.3ug/ml and 10.1ug/ml, respectively. The percent recovery of deferiprone was found to be within limit.The method was found to be robust even by change in flow rate, temperature, and wavelength. The developed method can be successfully employed in a routine analysis of deferiprone in pharmaceutical dosage form. Force degradation studies were also carried out by exposing the deferiprone samples in a various stress condition such as acidic, alkaline, hydrolytic, oxidative, thermal, photolytic degradation to establish the specificity of method.


Cite this article:
Bharti S Fegade, Aishwarya S. Mhatre, Vijay K. Munipalli, Hemant P Magar, Pankaj P Thakur, Ashok Kumar, Vaidun Bhaskar. Development and Validation of a Stability Indicating RP-HPLC Method for the Estimation of Deferiprone in its Capsule Dosage Form. Research Journal of Pharmacy and Technology. 2024; 17(6):2725-1. doi: 10.52711/0974-360X.2024.00427

Cite(Electronic):
Bharti S Fegade, Aishwarya S. Mhatre, Vijay K. Munipalli, Hemant P Magar, Pankaj P Thakur, Ashok Kumar, Vaidun Bhaskar. Development and Validation of a Stability Indicating RP-HPLC Method for the Estimation of Deferiprone in its Capsule Dosage Form. Research Journal of Pharmacy and Technology. 2024; 17(6):2725-1. doi: 10.52711/0974-360X.2024.00427   Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-6-46


8. REFERENCE:
1.    Brancaleoni V, Di Pierro E, Motta I, Cappellini MD. Laboratory diagnosis of thalassemia. International Journal of Laboratory Hematology. 2016; May; 38: 32-40. doi:10.1111/ijlh.12527
2.    Entezari S, Haghi SM, Norouzkhani N, Sahebnazar B, Vosoughian F, Akbarzadeh D, Islampanah M, Naghsh N, Abbasalizadeh M, Deravi N. Iron chelators in treatment of iron overload. Journal of Toxicology. 2022 May 5; 2022. doi:10.1155/2022/4911205
3.    Wijaya AB, Marhaeni W, Devi WR, Saputra M, Rahman G. Oxidative Stress and Renal Function in Pediatric Patients with Beta Thalassemia Major (β-TM) Receiving Deferiprone and Deferasirox: A Cross-Sectional, Single Center Study. Research Journal of Pharmacy and Technology. 2023 Mar 1; 16(3): 1225-30. doi: 10.52711/0974-360X.2023.00203
4.    Chaudhary JL, Rathi SG, Shah S, Patel JT, Vaghela S. Deferiprone (Ferriprox) as newer iron Chelator in Thalassaemia major patients. Research Journal of Pharmacy and Technology. 2021; 14(2): 1041-4. doi: 10.5958/0974-360X.2021.00186.4
5.    Marchande DD, Jain A. Deferiprone: A review of Analytical methods. International Journal of Pharmaceutical Research and Applications. 2022; Dec 22; 1724-30 doi: 10.35629/7781-070617241730
6.    Vedantika Das, Bhushan Bhairav, R. B. Saudagar. Quality by Design approaches to Analytical Method Development. Research Journal of Pharmacy and Technology 2017; 10(9): 3188-3194. doi: 10.5958/0974-360X.2017.00567.4
7.    Malik A, Firke S, Patil R, Shirkhedkar A, Kalaskar M. Development and validation of zero and first-order derivative area under curve spectrophotometric methods for the determination of deferiprone in bulk material and capsules. Asian Journal of Pharmaceutical Analysis. 2019; 9(2): 49-54. doi: 10.5958/2231-5675.2019.00011.5 
8.    Sachin kothawade N, vishal pande V. Development and validation of an rp-hplc method for deferiprone estimation in pharmaceutical dosage form. Asian Journal of Pharmaceutical and Clinical Research. 2023; April 7; 16(4): 100-03.doi: 10.22159/ajpcr.2023.v16i4.47000
9.    Mounika A, Kiran Kumar V. Method development and validation for deferiprone by RP-HPLC method.  Indo American Journal of Pharmaceutical Sciences. 2022; 09(12). doi: 10.5281/zenodo.7548262
10.    Sireesha KS, Sai Kiran BS, Sekhar KB, Muneer S. A new RP-HPLC method development and validation of deferiprone in bulk and its pharmaceutical dosage form. International Journal of Advanced Research. 2016; 4(8): 2174-9. doi: 10.21474/IJAR01/1435
11.    Abbas M, Nawaz R, Iqbal T, Alim M, Asi MR. Quantitative determination of deferiprone in human plasma by reverse phase high performance liquid chromatography and its application to pharmacokinetic study. Pakistan Journal of Pharmaceutical Sciences. 2012; Apr 1; 25(2).
12.    Fares MY, Hegazy MA, El-Sayed GM, Abdelrahman MM, Abdelwahab NS. Quality by design approach for green HPLC method development for simultaneous analysis of two thalassemia drugs in biological fluid with pharmacokinetic study. RSC Advances. 2022; 12(22): 13896-916. doi: 10.1039/D2RA00966H
13.    Sutar S, Patil P, Marchande D, Patil S, Bandgar S, Kumbhar R. RP-HPLC Method Development for Simultaneous Estimation of Oral Iron Chelator Deferiprone and its related Impurity. Research Journal of Pharmacy and Technology. 2023; Apr 29; 16(4): 1890-4. doi: 10.52711/0974-360X.2023.00310.
14.    Asmari M, Abdel-Megied AM, Michalcová L, Glatz Z, El Deeb S. Analytical approaches for the determination of deferiprone and its iron (III) complex: Investigation of binding affinity based on liquid chromatography-mass spectrometry (LC-ESI/MS) and capillary electrophoresis-frontal analysis (CE/FA). Microchemical Journal. 2020; May 1; 154: 104556.  doi: 10.1016/j.microc.2019.104556
15.    Guideline ICH. Validation of analytical procedures: text and methodology. Q2 (R1). 2005; Nov; 1(20): 05.
16.    Raul SK, Padhy GK, Mahapatra AK, Charan SA. An overview of concept of pharmaceutical validation. Research Journal of Pharmacy and Technology. 2014; 7(9): 1081-90.
17.    Sowmya HG, Priya M, Murugan V. Implementation of quality by design approach for method development and validation: A review. Research Journal of Pharmacy and Technology. 2022; 15(1): 436-40. doi: 10.52711/0974-360X.2022.00072
18.    Dara SK, Tiwari RN. Pharmaceutical process validation: An industrial perspective. Research Journal of Pharmacy and Technology. 2014; 7(7): 810-4.
19.    Jetani JM, Pai KG. A comparative review of the USFDA guidelines on process validation focusing on the importance of quality by design (QbD). Research Journal of Pharmacy and Technology. 2017; 10(4): 1257-60. doi: 10.5958/0974-360X.2017.00223.2
20.    Sutar SV, Yeligar VC, Patil SS. Stability Indicating Forced Degradation Studies. Research Journal of Pharmacy and Technology. 2019; 12(1): 429-33. doi: 10.5958/0974-360X.2019.00078.7
21.    Kushwaha P. Significance of Stability Studies on Degradation Product. Research Journal of Pharmacy and Technology. 2009; 2(4): 621-7.

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available